Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. 10-K Item 1C cybersecurity disclosure for fiscal year 2025. The filing describes the company's cybersecurity risk management framework, governance structure, and oversight processes. No specific cybersecurity incident is disclosed. The company uses a risk-based approach including network security controls, email security tools, third-party managed detection and response, penetration testing, and employee training. The Audit Committee oversees cybersecurity risk management.